JeffreySchneiderMD

Oncology • Mineola, NY

Thoracic Cancer

Physician

Join to view full profile

Dr. Schneider is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schneider's full profile

Already have an account?

Office
120 Mineola Blvd
Mineola, NY 11501
Phone+1 516-663-9500

Fax+1 516-663-4613

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1989 - 1992
NYU Grossman School of MedicineResidency, Internal Medicine, 1986 - 1989
Yale School of MedicineClass of 1986
Yale University School of MedicineClass of 1986

Certifications & Licensure

NY State Medical License 1987 - 2025
NY State Medical License 1987 - 2025
PA State Medical License 1999 - 2005
PA State Medical License 1999 - 2005
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Top MD Consumers Checkbook

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3

Publications & Presentations

PubMed

416 citations
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinic...
Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth, Ki Hyeong Lee, Alexander Luft
JAMA Oncology. 2020-05-01
13 citations
Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (M...
Edward B. Garon, Byoung Chul Cho, Niels Reinmuth, Ki Hyeong Lee, Alexander Luft
Clinical Lung Cancer. 2021-02-19
29 citations
Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)
David R. Spigel, Robert M. Jotte, John Nemunaitis, Merrill Kingman Shum, Jeffrey A. Schneider
Journal of Thoracic Oncology. 2021-02-01

Press Mentions

Long Islanders with Weakened Immune Systems Still Wary of COVID-19June 14th, 2021
Evolving Issues in Low-Dose CT Lung Cancer ScreeningAugust 15th, 2013